Recombinant Human AKR7A2 cell lysate
Cat.No. : | AKR7A2-52HCL |
- Specification
- Gene Information
- Related Products
- Download
Description : | Aldo-keto reductases, such as AKR7A2, are involved in the detoxification of aldehydes and ketones. |
Species : | Human |
Size : | 100 ul |
Storage Buffer : | 1X Sample Buffer (50 mM Tris-HCl, 2% SDS, 10% glycerol, 300 mM 2-mercaptoethanol, 0.01% Bromophenol blue) |
Applications : | Western Blot; |
Tag : | Non |
Gene Name : | AKR7A2 aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) [ Homo sapiens ] |
Official Symbol : | AKR7A2 |
Synonyms : | AKR7A2; aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase); aflatoxin B1 aldehyde reductase member 2; AFAR; AFB1-AR 1; SSA reductase; aldoketoreductase 7; AFB1 aldehyde reductase 1; succinic semialdehyde reductase; aflatoxin beta1 aldehyde reductase; AKR7; AFAR1; AFB1-AR1; |
Gene ID : | 8574 |
mRNA Refseq : | NM_003689 |
Protein Refseq : | NP_003680 |
MIM : | 603418 |
UniProt ID : | O43488 |
Chromosome Location : | 1p36.13 |
Pathway : | Metabolism of xenobiotics by cytochrome P450, organism-specific biosystem; Metabolism of xenobiotics by cytochrome P450, conserved biosystem; |
Function : | alditol:NADP+ 1-oxidoreductase activity; electron carrier activity; oxidoreductase activity; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor; phenanthrene-9,10-epoxide hydrolase activity; |
Products Types
◆ Recombinant Protein | ||
AKR7A2-123R | Recombinant Rhesus Macaque AKR7A2 Protein, His (Fc)-Avi-tagged | +Inquiry |
AKR7A2-259R | Recombinant Rat AKR7A2 Protein, His (Fc)-Avi-tagged | +Inquiry |
AKR7A2-176H | Recombinant Human AKR7A2 Protein, GST-tagged | +Inquiry |
AKR7A2-418H | Recombinant Human AKR7A2 Protein, GST-tagged | +Inquiry |
AKR7A2-295R | Recombinant Rhesus monkey AKR7A2 Protein, His-tagged | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Reviews
- Q&As
Customer Reviews (4)
Write a reviewThe AKR7A2 protein stands out as a protein of exceptional quality, perfectly suited to meet the experimental needs of researchers.
One remarkable aspect of working with the AKR7A2 protein is the excellent technical support provided by its manufacturer.
With its reliable performance and consistent results, the AKR7A2 protein provides researchers with the confidence and accuracy required for successful experimentation.
Whether utilized in protein-protein interaction studies or enzymatic assays, this protein exhibits robust performance, enabling accurate data generation and analysis.
Q&As (21)
Ask a questionYes, dysregulation of AKR7A2 has been implicated in several diseases. Reduced AKR7A2 expression or activity has been linked to increased susceptibility to oxidative stress-induced tissue damage, cancer development, and age-related diseases such as Alzheimer's disease and Parkinson's disease. On the other hand, overexpression or altered activity of AKR7A2 may contribute to drug resistance in some cancer cells.
AKR7A2 has shown potential as a biomarker for certain diseases and drug response. For example, its expression levels have been correlated with drug resistance in some cancer cells, making it a potential biomarker for predicting treatment response. Additionally, altered AKR7A2 expression or activity has been observed in neurodegenerative diseases, suggesting its potential as a biomarker for disease prognosis.
Yes, genetic variations and mutations have been reported in the AKR7A2 gene. Some of these variations are associated with altered enzyme activity or expression levels of AKR7A2. Certain genetic variants may also confer susceptibility to certain diseases or impact drug metabolism.
Yes, AKR7A2 plays a role in drug metabolism. It is involved in the detoxification and elimination of certain drugs and their metabolites from the body. This activity helps protect cells and tissues from drug-induced damage.
AKR7A2 is widely expressed in various tissues throughout the body, including the liver, kidney, lung, brain, and gastrointestinal tract. It is also present in certain cancer cells.
Yes, there are ongoing research studies on AKR7A2 protein. Scientists are continuing to investigate its role in drug metabolism, detoxification pathways, and its potential as a therapeutic target for various diseases. Additionally, researchers are exploring the use of AKR7A2 as a biomarker for disease prognosis and drug response.
Yes, AKR7A2 has the potential to be a target for drug development. Its involvement in drug metabolism and detoxification pathways makes it an attractive target for enhancing the efficacy of certain drugs or developing novel therapeutics. However, further research is needed to fully understand its role and to identify specific inhibitors or activators that can be used as pharmaceutical agents.
Several compounds have been identified as inhibitors of AKR7A2, such as flufenamic acid and naproxen. On the other hand, there is limited information available about activators of AKR7A2. Further research is needed to identify specific modulators of AKR7A2 activity.
AKR7A2 plays a role in drug metabolism by catalyzing the conversion of reactive aldehydes generated during drug metabolism into inactive and easily excretable forms. This detoxification process helps eliminate potentially harmful metabolites and promotes drug clearance from the body. Therefore, AKR7A2 can affect the efficacy and toxicity of certain drugs.
AKR7A2 acts on a wide range of substrates, including aldehydes derived from lipid peroxidation, such as 4-HNE, as well as endogenous and exogenous carbonyl compounds, pharmaceutical drugs, and toxins. It catalyzes the reduction of these substrates to their corresponding alcohols.
Mutations in the AKR7A2 gene have been linked to a rare genetic disorder called autosomal recessive adult-onset motor neuron disease (AR-AMN). This disease is characterized by a slowly progressive movement disorder and distal limb muscle weakness. The exact role of AKR7A2 in this disease is not fully understood.
Yes, genetic variations and polymorphisms have been identified in the AKR7A2 gene. These variations can result in different forms of the AKR7A2 protein with altered enzymatic activity or stability. Some of these polymorphisms have been associated with an increased risk for certain diseases or altered drug metabolism.
Several compounds have been identified as inhibitors or activators of AKR7A2. For example, some nonsteroidal anti-inflammatory drugs (NSAIDs) and their metabolites have been shown to inhibit AKR7A2 activity. On the other hand, certain dietary compounds such as curcumin and resveratrol have been found to activate AKR7A2 expression and increase its enzymatic activity.
Due to its detoxification capabilities, AKR7A2 has been explored as a potential target for therapeutic intervention in conditions associated with aldehyde toxicity, such as neurodegenerative diseases and oxidative stress-related disorders. Developing drugs that modulate or enhance AKR7A2 activity could be a potential avenue for future treatments.
The activity of AKR7A2 can be regulated at multiple levels. It is known to undergo post-translational modifications, such as phosphorylation and acetylation, which can affect its enzymatic activity and stability. Additionally, the expression of AKR7A2 can be influenced by various transcription factors and signaling pathways, such as the Nrf2/ARE pathway, which is involved in response to oxidative stress.
Yes, AKR7A2 has several physiological functions. It is involved in the detoxification of reactive aldehydes and other toxic carbonyl compounds. Additionally, AKR7A2 participates in oxidative stress response, lipid metabolism, and protection against DNA damage.
AKR7A2 is predominantly expressed in the liver, but it is also present in various tissues including the brain, kidney, lung, and testis. It is localized in the cytoplasm of cells.
AKR7A2 plays a critical role in the detoxification of reactive aldehydes and carbonyl compounds, thus protecting cells from their potentially toxic effects. It is involved in the metabolism of drugs, toxins, and endogenous aldehydes like 4-hydroxynonenal (4-HNE), which is a product of lipid peroxidation.
Yes, AKR7A2 has been implicated in drug resistance in cancer cells. Increased expression or altered activity of AKR7A2 can lead to enhanced detoxification of anticancer drugs, reducing their effectiveness against tumor cells. This drug resistance mechanism has been observed in various cancer types and underscores the importance of understanding the role of AKR7A2 in drug response.
The expression and activity of AKR7A2 can be regulated by various factors. For example, the AKR7A2 gene expression can be induced by oxidative stress and certain chemicals through activation of specific transcription factors. Post-translational modifications, such as phosphorylation, can also modulate AKR7A2 activity.
AKR7A2 has been implicated in the development of diabetic complications, particularly diabetic nephropathy. It is thought to be involved in the metabolism of glucose and related byproducts, as well as the detoxification of reactive aldehydes generated in diabetic conditions.
Ask a Question for All AKR7A2 Products
Required fields are marked with *
My Review for All AKR7A2 Products
Required fields are marked with *
Inquiry Basket